A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs ADXS 31142 (Primary) ; Pembrolizumab (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Acronyms KEYNOTE-046
  • Sponsors Advaxis
  • Most Recent Events

    • 02 Apr 2018 According to an Advaxis media release, data from this trial has been accepted for presentation at American Society of Clinical Oncology Annual Meeting 2018.
    • 13 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 02 Aug 2017 According to an Advaxis media release, two poster presentations featuring preliminary immune correlative data from this trial will were selected for presentation at the third annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top